Advertisement

Clinical Research in Cardiology

, Volume 109, Issue 1, pp 128–130 | Cite as

Antithrombotic therapy in atrial fibrillation: stop triple therapy and start optimizing dual therapy?

  • Bernhard Wernly
  • Michael Lichtenauer
  • David Erlinge
  • Christian JungEmail author
Letter to the Editors

Sirs:

Based on recent studies, we want to provoke thoughts on how to further optimize research on antiplatelet treatment in patients on oral anticoagulation (OAC).

One in three patients suffering from atrial fibrillation (AF) develops concomitant coronary artery disease. Hence, these patients are likely to undergo percutaneous coronary intervention (PCI). AF often leads to an indication for OAC, and after PCI, a dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 inhibitor is recommended. These overlapping recommendations led to many patients with AF after PCI and/or acute coronary syndrome (ACS) being on “triple therapy” (TT) consisting of OAC and DAPT. In TT, both non-vitamin-K-anticoagulants (NOACs) and vitamin-K-antagonists (VKA) are used. TT is thought to be effective in preventing thrombotic events, but known to be associated with risks of bleeding. This is of interest, as AF patients are often elderly and, therefore, at greater risk for bleeding complications....

References

  1. 1.
    Cannon CP, Bhatt DL, Oldgren J et al (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377:1513–1524CrossRefGoogle Scholar
  2. 2.
    Gibson CM, Mehran R, Bode C et al (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375:2423–2434CrossRefGoogle Scholar
  3. 3.
    Dewilde WJ, Oirbans T, Verheugt FW et al (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381:1107–1115CrossRefGoogle Scholar
  4. 4.
    Lopes RD, Heizer G, Aronson R et al (2019) Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 380:1509–1524CrossRefGoogle Scholar
  5. 5.
    Cavallari I, Patti G (2018) Meta-analysis comparing the safety and efficacy of dual versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Am J Cardiol 121:718–724CrossRefGoogle Scholar
  6. 6.
    Lou B, Liang X, Wu Y et al (2018) Meta-analysis comparing dual versus single antiplatelet therapy in combination with antithrombotic therapy in patients with atrial fibrillation who underwent percutaneous coronary intervention with stent implantation. Am J Cardiol 122:604–611CrossRefGoogle Scholar
  7. 7.
    Golwala HB, Cannon CP, Steg PG et al (2018) Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J 39:1726–1735CrossRefGoogle Scholar
  8. 8.
    Duerschmied D, Brachmann J, Darius H et al (2018) Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials? Clin Res Cardiol 107:533–538CrossRefGoogle Scholar
  9. 9.
    Lee SY, Hong MK, Shin DH et al (2017) Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors. Clin Res Cardiol 106:165–173CrossRefGoogle Scholar
  10. 10.
    Vranckx P, Valgimigli M, Juni P et al (2018) Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 392:940–949CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019
corrected publication 2019

Authors and Affiliations

  1. 1.Department of Cardiology, Clinic of Internal Medicine IIParacelsus Medical UniversitySalzburgAustria
  2. 2.Department of Cardiology, Clinical SciencesLund UniversityLundSweden
  3. 3.Division of Cardiology, Pulmonology, and Vascular Medicine, Medical FacultyUniversity of DüsseldorfDüsseldorfGermany

Personalised recommendations